MYND Life Sciences Inc. (CSE:MYND)
Canada · Delayed Price · Currency is CAD | Market Cap | 5.22M +211.8% |
| Revenue (ttm) | 1.00 |
| Net Income | -542.57K |
| EPS | -0.01 |
| Shares Out | 74.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Open | 0.0300 |
| Previous Close | 0.0700 |
| Day's Range | 0.0300 - 0.0700 |
| 52-Week Range | 0.0100 - 0.1400 |
| Beta | 0.93 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 25, 2026 |
About MYND Life Sciences
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada. [Read more]
Financial Performance
Financial StatementsNews
MYND Life Sciences Announces Shares for Debt Transaction
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2025) - MYND Life Sciences Inc. (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to ...
MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the de...
MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the de...
MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a leader in mental health diagnostics and treatments, today...
MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the deve...
MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") The Company is pleased to welcome Ms. Laurie Bakke who was re...
MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a pioneering biopharmaceutical research and development comp...
Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), We are delighted to announce the appointment of Mynd Life Sc...
MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.
Potential merger to create new industry leader. Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a pioneering...
MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures
MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disorders Vancouver, Brit...
MYND Life Sciences Inc. Has Management CTO Revoked
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating inn...
MYND Life Sciences Inc. Provides Default Status Report
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating ...
MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status Report
Global expansion as MYND executes non-binding MOU with German based Oxygen Handel. Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND...
MYND Life Sciences Inc. Achieves a Major Milestone and Provides Default Status Report
Identification of a potent, monomolecular non-hallucinogenic analog of psilocybin 100 times stronger than psilocybin. Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - MYND Life Science...
MYND Life Sciences Inc. Granted Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors...
MYND Life Sciences Announces the Sale of Leasehold Tenant Improvements and Health Canada Cannabis License
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company cr...
MYND Life Sciences Announces Stock Option Grant
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company"), a biopharmaceutical research and development company cre...
Mynd Life Sciences Terminates Proposed Transaction with Tidal Psychedelics
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company") announces that it has terminated the non-binding memorandum...
MYND Life Sciences Announces Chief Scientific Officer, Dr. Wilf Jefferies, Induction as a National Academy of Inventors Fellow
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company"), a biopharmaceutical research and development company creat...
MYND Life Sciences Announces New Testing Methodologies for Measuring Cellular Responses to Microdosing with Psilocybins
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2022) - Mynd Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("Mynd" or the "Company"), a biopharmaceutical research and development company creati...
MYND Life Sciences Announces $3.5 Million Share Offering
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), is pleased to announce that it plans to undertake a non-b...
MYND Life Sciences Executes a Non-Binding MOU with Tidal Psychedelics
MYND expresses the intention to acquire all the issued and outstanding shares of Tidal PsychedelicsVancouver, British Columbia--(Newsfile Corp. - March 16, 2022) - MYND Life Sciences Inc. (CSE: MYND) ...
MYND Life Sciences Inc. Announces the Recruitment of a Senior Operations and Research Manager
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2022) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or "the Company") announces the hiring of a Senior Operations and Research Ma...
MYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial
Clinical validation of MYND Diagnostics' proprietary biomarkers in evaluating the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression VANCOUVER, BC , Feb. 8, 2022 /PRNewswi...
MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia
MYND's Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /PRNewswire/ - MYND Life Sciences Inc. ("MYND" or the "Company") (CSE: MYND) (OTC: MYN...